{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:30:39Z","timestamp":1785295839532,"version":"3.55.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Infections due to multidrug- and extensively drug-resistant bacteria can be difficult to treat and are associated with high mortality and burden of disease. Ceftazidime-avibactam (CVA) is used in patients with multidrug-resistant Gram-negative bacterial infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the real-world usage, effectiveness, and antimicrobial features of CVA in clinical practice in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, prospective observational study collected medical record data from adult patients (\u226518 years) who had been hospitalized and treated with \u22651 dose of CVA. Clinical and microbiological outcomes were evaluated at the end of treatment, with clinical cure defined as resolution of infection following treatment with CVA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Data were obtained from 220 adult patients receiving \u22651 dose of CVA in China. Infections indicated for CVA included pneumonia (64.5%), complicated intra-abdominal infection (16.8%) and bloodstream infection (7.3%).\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      (129\/227 isolates, 56.8%) was the most commonly identified pathogen, followed by\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      (33 isolates, 14.5%). Of 87\u00a0K\n                      <jats:italic>. pneumoniae<\/jats:italic>\n                      isolates, 76 (87.4%) were meropenem resistant and the same proportion carried cabapenemase genes. Low levels of resistance to CVA were observed across all isolates. Three-quarters of patients received CVA as definitive therapy. Clinical cure at end of treatment was achieved in 66.4% of patients and microbiological success in 69.6% of patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Findings from this study provide important real-world data on treatment patterns, microbiological features, and clinical and microbiological outcomes for CVA in routine clinical practice in China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2025.1663392","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:40:24Z","timestamp":1769496024000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world usage, effectiveness, and microbiological features of ceftazidime-avibactam in clinical practice in China"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiaohua","family":"Qin","sequence":"first","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxin","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The First Affiliated Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoju","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Henan Provincial People\u2019s Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuzhu","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Beijing Tsinghua Changgung Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Liver Diseases and Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Shanghai Tenth People\u2019s Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Ningbo University Medical College","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongjie","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Tianjin Medical University General Hospital","place":["Heping, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renru","family":"Han","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Cao","sequence":"additional","affiliation":[{"name":"China Medical, Pfizer Inc","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Su","sequence":"additional","affiliation":[{"name":"China Medical, Pfizer Inc","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchao","family":"Lu","sequence":"additional","affiliation":[{"name":"China Medical, Pfizer Inc","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Xu","sequence":"additional","affiliation":[{"name":"China Medical, Pfizer Inc","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Yin","sequence":"additional","affiliation":[{"name":"China Medical, Pfizer Inc","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Lu","sequence":"additional","affiliation":[{"name":"China Medical, Pfizer Inc","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Yang","sequence":"additional","affiliation":[{"name":"China Medical, Pfizer Inc","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minggui","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/s1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2147\/IDR.S350976","article-title":"Ceftazidime\/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant Pseudomonas aeruginosa Infection","volume":"15","author":"Chen","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00314","article-title":"Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant enterobacteriaceae isolated from adult and children patients in China","volume":"10","author":"Han","year":"2020","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz522","article-title":"Real-world experience with ceftazidime-avibactam for multidrug-resistant gram-negative bacterial infections","volume":"6","author":"Jorgensen","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"107418","DOI":"10.1016\/j.ijantimicag.2024.107418","article-title":"Comparing ceftazidime\/avibactam and polymyxin B for treating carbapenem-resistant organisms infections: A propensity score-matched retrospective cohort study","volume":"65","author":"Liu","year":"2025","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1533952","article-title":"The efficacy and safety of ceftazidime\/avibactam or polymyxin B based regimens for carbapenem-resistant Pseudomonas aeruginosa infection: a multicenter real-world and propensity score-matched study","volume":"16","author":"Long","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B10","unstructured":"ZAVICEFTA (Ceftazidime-Avibactam)\n          \n          \n          \n          2024"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2025.105036","article-title":"Real-world use, effectiveness, and safety of ceftazidime-avibactam: Results of the French cohort OZAVIE","volume":"55","author":"Piroth","year":"2025","journal-title":"Infect. Dis. Now"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae052","article-title":"Antimicrobial resistance of clinical bacterial isolates in China: current status and trends","volume":"6","author":"Qin","year":"2024","journal-title":"JAC Antimicrob. Resist."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106872","article-title":"Real-world effectiveness of ceftazidime\/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections","volume":"62","author":"Qu","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.3390\/healthcare11131946","article-title":"Antimicrobial resistance: A growing serious threat for global public health","volume":"11","author":"Salam","year":"2023","journal-title":"Healthcare (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40121-023-00762-9","article-title":"The use and effectiveness of ceftazidime-avibactam in real-world clinical practice: EZTEAM study","volume":"12","author":"Soriano","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases society of america 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin. Infect. Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e70234","DOI":"10.7759\/cureus.70234","article-title":"Real-world evidence on use of ceftazidime-avibactam in the management of gram-negative infections: A retrospective analysis","volume":"16","author":"Todi","year":"2024","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"B19","unstructured":"Drugs@FDA: FDA-approved drugs\n          \n          \n          \n          2025"},{"key":"B20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"B22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jiph.2022.02.003","article-title":"Analysis of the clinical application of ceftazidime-avibactam in China","volume":"15","author":"Wang","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2147\/IDR.S347343","article-title":"Prevalence of carbapenem-resistant klebsiella pneumoniae infection in a northern province in China: clinical characteristics, drug resistance, and geographic distribution","volume":"15","author":"Wang","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"B24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","article-title":"Novel beta-lactamase inhibitors: unlocking their potential in therapy","volume":"77","author":"Wong","year":"2017","journal-title":"Drugs"},{"key":"B25","volume-title":"WHO bacterial priority pathogens list 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance","year":"2024"},{"key":"B26","doi-asserted-by":"publisher","first-page":"7227","DOI":"10.2147\/IDR.S435882","article-title":"Clinical efficacy and safety evaluation of ceftazidime-avibactam in the treatment of klebsiella pneumoniae infection: A retrospective analysis from a hospital in China","volume":"16","author":"Xu","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"B27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s44280-023-00009-9","article-title":"Current status and trends of antimicrobial resistance among clinical isolates in China: a retrospective study of CHINET from 2018 to 2022","volume":"1","author":"Yang","year":"2023","journal-title":"One Health Adv."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2025.102735","article-title":"Real-world use and treatment outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan: A multicenter retrospective study","volume":"18","author":"Yang","year":"2025","journal-title":"J. Infect. Public Health"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e070491","DOI":"10.1136\/bmjopen-2022-070491","article-title":"Efficacy and safety of ceftazidime-avibactam versus polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infection: a systematic review and meta-analysis","volume":"13","author":"Yang","year":"2023","journal-title":"BMJ Open"},{"key":"B30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/phar.1622","article-title":"The beta-lactams strike back: ceftazidime-avibactam","volume":"35","author":"Zasowski","year":"2015","journal-title":"Pharmacotherapy"},{"key":"B31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s15010-024-02324-8","article-title":"Ceftazidime\/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study","volume":"53","author":"Zhuang","year":"2025","journal-title":"Infection"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1663392\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:40:26Z","timestamp":1769496026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1663392\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":31,"alternative-id":["10.3389\/fcimb.2025.1663392"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1663392","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"article-number":"1663392"}}